Citius Oncology (CTOR) said Tuesday it has entered into an exclusive distribution agreement with Greece-based Integris Pharma to make Lymphir available in Southern Europe.

The partnership coverage includes Greece, Cyprus, Malta, Bulgaria, and Romania, it said. Lymphir is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma.

The deal is part of its Named Patient Programs, also known as early access programs, Citius said, adding that it is in discussions with distribution partners to make the drug available through the program in Europe, South America and the Middle East.

Price: 1.90, Change: +0.03, Percent Change: +1.66